• Paul G Richardson, Jacob P Laubach, Sagar Lonial, Philippe Moreau, Sung-Soo Yoon, Vânia T M Hungria, Meletios A Dimopoulos, Meral Beksac, Melissa Alsina, and Jesús F San-Miguel.
• Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
• Expert Rev Anticancer Ther. 2015 Jan 1; 15 (7): 737-48.

AbstractOutcomes for patients with multiple myeloma (MM) have improved significantly over the past decade. Despite these advances, MM remains incurable and an unmet medical need remains for patients who are relapsed and/or refractory. Panobinostat is a potent, oral pan-deacetylase inhibitor that elicits anti-myeloma activity through epigenetic modulation of gene expression and disruption of protein metabolism. Preclinical data demonstrated that panobinostat has synergistic effects on myeloma cells when combined with bortezomib and dexamethasone. In a Phase III clinical trial evaluating bortezomib and dexamethasone in combination with panobinostat or placebo in patients with relapsed or relapsed and refractory MM (PANORAMA 1), panobinostat led to a significant increase in median progression-free survival. Panobinostat is currently under regulatory review with a recent accelerated approval granted for the treatment of relapsed disease, in which both bortezomib and immunomodulatory drugs have failed. Here, we summarize the preclinical, pharmacokinetic and clinical data for panobinostat in MM.

27 keywords...

hide…